Current Edition

age-related macular degeneration

FDA greenlights Genentech’s eye implant for macular degeneration. Will it be a tough sell?

Two treatments per year as opposed to 12, what’s not to like? In two words—surgical implants. That’s the stigma Genentech will potentially face as it …

Continue Reading →
Biogen

Biogen beefs up in biosimilars—again—with FDA nod for Samsung-partnered Lucentis copycat

Even as Biogen dominates biopharma headlines with its high-profile Aduhelm launch, the company’s budding biosimilar business has been quietly building up—and now, it has another …

Continue Reading →